MC2 therapeutics is converting research in skin biology into novel treatment paradigms for immune-mediated and inflammatory conditions initially focusing on manifestations in the skin.
Our innovative approach is anchored in deep understanding of skin biology – knowledge that can also be leveraged to inform approaches in other types of immune-mediated and inflammatory diseases outside of this area. Fuelled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with immune-mediated and inflammatory skin conditions.
Our discoveries and clinical programs in urea associated skin diseases CKD-aP, Vulvar Lichen Sclerosus and oral treatment of Hidradenitis Suppurativa are just the beginning. We also apply our expertise in formulation and clinical development to ensure treatment satisfaction for the patients and release of the full clinical potential of therapies.
There is a major unmet need to significantly upgrade the patient treatment experience focusing on the three essentials:
(i) EFFICACY: Fast onset and high efficacy;
(ii) TOLERABILITY: Favourable tolerability and safety profile;
(iii) ADHERENCE: Therapies and dosage formats that motivate high adherence in daily routines.